About Biological E
Biological E is a company based in Hyderabad (India) founded in 1953 by Datla Venkata Krishnam Raju. The company has 1 employees as of September 20, 2024. Biological E has completed 2 acquisitions, including Akorn and Akorn India. Biological E offers products and services including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine. Biological E operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Altimmune, among others.
- Headquarter Hyderabad, India
- Employees 1 as on 20 Sep, 2024
- Founders Datla Venkata Krishnam Raju
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biological E. Limited
- Jurisdiction Andhra Pradesh, Telangana, India
-
Annual Revenue
$316.36 M (USD)-29.92as on Mar 31, 2024
-
Net Profit
$94.65 M (USD)-15.09as on Mar 31, 2024
-
EBITDA
$78.24 M (USD)-45.74as on Mar 31, 2024
-
Latest Funding Round
$50 M (USD), Grant
Oct 24, 2021
-
Investors
International Finance Corporation
& 1 more
-
Employee Count
1
as on Sep 20, 2024
-
Investments & Acquisitions
Akorn
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biological E
Biological E offers a comprehensive portfolio of products and services, including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine.
Vaccine for preventing SARS-CoV2 infections.
Vaccine to prevent Hepatitis B disease.
Combined vaccine for diphtheria, tetanus, pertussis, hepatitis B, and Hib.
Vaccine against typhoid fever in children and adults.
People of Biological E
Unlock access to complete
Funding Insights of Biological E
Investors in Biological E
Biological E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include International Finance Corporation and DFC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency supporting the development of SMEs
|
Locked | Locked | Locked | |
|
IFC is focused on private sector development in emerging markets.
|
Locked | Locked | Locked |
Investor details for Biological E
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biological E
Biological E has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Akorn and Akorn India.
Investment portfolio details for Biological E
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Sterile pharmaceuticals are developed, manufactured, and marketed by Akorn India.
|
Locked | Locked | 2011 | Locked | |
|
Injectable and ophthalmic pharmaceutical products were manufactured across therapeutic areas.
|
Locked | Locked | 1948 | Locked |
Complete acquisition details for Biological E
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biological E
Detailed financials for Biological E
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biological E Comparisons
Peer comparison for Biological E
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biological E
Biological E operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Altimmune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
Detailed competitors of Biological E
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biological E
Complete news archive for Biological E
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biological E
Biological E was founded in 1953 and raised its 1st funding round 67 years after it was founded.
Biological E is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Mahima Datla is the current CEO of Biological E.
As of Sep 20, 2024, the latest employee count at Biological E is 1.
Annual revenue of Biological E is $316.36M as on Mar 31, 2024.
Biological E was founded in 1953 in Hyderabad, India, as a biopharmaceutical company. Innovative vaccines, branded generics, and novel therapeutics are developed, manufactured, and marketed globally. The product pipeline encompasses pneumococcal conjugate vaccine, Hib vaccine, poliomyelitis vaccine, COVID-19 vaccine, hepatitis A vaccine, and measles vaccine. Operations are centered on addressing various infectious diseases through research and production.
Biological E's top competitors include Vaxcyte, Serum Institute of India and RedHill Biopharma.
Biological E offers CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine.
Biological E has made 2 acquisitions, including Akorn, and Akorn India.
Biological E has 2 investors. Key investors include International Finance Corporation, and DFC.